Article Text

PDF

Cardiac troponin I release after transcatheter atrial septal defect closure depends on occluder size but not on patient’s age
  1. A Tárnok1,
  2. J Bocsi1,
  3. P Osmancik2,
  4. H-J Häusler3,
  5. P Schneider3,
  6. I Dähnert3
  1. 1Research Laboratory, Department of Paediatric Cardiology, Heart Centre, University Hospital, Leipzig, Germany
  2. 2Cardiac Centre, Department of Paediatric Cardiology, University Hospital Kralovske Vinogrady, Prague, Czech Republic
  3. 3Department of Paediatric Cardiology, Heart Centre, University Hospital, Leipzig, Germany
  1. Correspondence to:
    Dr Attila Tárnok
    Department of Paediatric Cardiology, Heart Centre, University of Leipzig, Strümpellstrasse 39, 04289 Leipzig, Germany; tarnokmedizin.uni-leipzig.de

Abstract

Objective: To examine whether transcatheter closure of secundum atrial septal defect (ASD) with the Amplatzer septal occluder leads to more myocardial injury in children than in adults.

Design: In a prospective study with children and adults cardiac troponin I (cTnI) serum concentrations were determined by immunoassay (AxSYM, Abbott Laboratories) before, during, and up to 20 months after surgical or transcatheter ASD closure.

Patients: Four groups of patients were studied: transcatheter ASD closure (group 1: 22 children, age range 3.26–14.7 years; group 2: 22 adults, 18.0–67.3 years), surgical ASD closure (group 3: 18 children, 3.12–13.5 years), and diagnostic catheterisation (group 4: 12 children, 2.68–15.0 years).

Results: cTnI concentrations were significantly increased after occluder implantation with higher serum concentrations in children than in adults (immediately after implantation: group 1, 3.2 (4.4) μg/l; group 2, 1.1 (4.2) μg/l; four hours after implantation: group 1, 4.8 (5.0) μg/l; group 2, 1.7 (2.3) μg/l; both p < 0.01, group 1 v group 2; one day after implantation: group 1, 3.0 (5.7) μg/l; group 2, 2.2 (5.2) μg/l) but were less than 20% of those after surgical ASD closure (group 3; p < 0.001) where the highest cTnI concentration was found (37.1 (26.3) μg/l). Diagnostic catheterisation (group 4) was not associated with detectable cTnI increase. From the cTnI concentrations the total amount of cTnI released after ASD closure was estimated for each patient. This was dependent on the size of the occluder (p < 0.05) but not on the patient’s age or procedural duration.

Conclusion: In regard to interventional ASD closure our data do not provide evidence that the child’s myocardium is more vulnerable. Transcatheter ASD closure induces minor myocardial lesion, the extent of which depends on the size of the Amplatzer septal occluder but is irrespective of the patient’s age.

  • ASD, atrial septal defect
  • AUC, area under the curve
  • cTnI, cardiac troponin I
  • atrial septal defect
  • paediatric cardiology
  • Amplatzer septal occluder
  • myocardial damage

Statistics from Altmetric.com

The Amplatzer septal occluder has proved to be a versatile and safe system for the occlusion of secundum atrial septal defect (ASD) and its high success rate has led to its widespread use.1–4 Interventional ASD occlusion produces much lower myocardial damage5 than does surgical ASD closure.6 However, little is known about myocardial lesions after occluder implantation in children. There are indications that the sensitivity of the myocardium to surgical trauma is inversely related to the patient’s age, with higher vulnerability among children.7

Cardiac troponin I (cTnI) is a sensitive and specific marker for myocardial damage. It is detectable only in traces in the peripheral blood of healthy people.7,8 cTnI increase is widely used for the diagnosis of myocardial infarction8,9 and its concentration is increased after cardiac surgery7,10,11 with maximum values 6–10 hours after surgery.7,11 The duration of ischaemic time correlates most strongly with the release of cTnI.7 Catheter intervention and radiofrequency ablation also lead to myocardial injury with increased cTnI.12,13 The specific mechanism of myocardial injury in interventional ASD closure in not yet fully understood. The influence of the size of the defect and of the closure device has not been studied. It is not clear whether the size of the septal defect also contributes to myocardial damage.

To investigate the effect of age on myocardial damage related to occluder implantation we measured the serum concentrations of cTnI before and after catheter intervention in children and adults and compared the data with surgical ASD closure and diagnostic cardiac catheterisation.

METHODS

Patients and study design

Four groups of patients were studied prospectively (table 1): children (group 1, n  =  22) and adults (group 2, n  =  22) who underwent Amplatzer occlusion of ASD (occluder diameter 12–34 mm, implantation with transoesophageal echocardiography and fluoroscopy guidance, exclusion criterion diagnostic endomyocardial biopsy), children (group 3, n  =  18) with surgical ASD closure (ASD closure by a homologous pericardial patch with median sternotomy, extracorporeal circulation, bypass time 27–58 minutes with aortic cross clamping 12–35 minutes, hypothermia 28–35°C, hypothermia time 20–60 minutes, postoperative mechanical ventilation 4–6 hours), and children (group 4, n  =  12) with diagnostic cardiac catheterisation without intervention (ventricular septal defect (n  =  5), coarctation of the aorta (n  =  5), other diagnosis (n  =  2)). The study was reviewed by the ethical committee of the University of Leipzig and informed consent was obtained from patients or their parents before the individual procedure. Pulmonary to systemic flow ratios in groups 1, 2, and 3 ranged from 1.5:1 to 3:1. Amplatzer septal occluders were implanted under intubation with propofol, alfentanil, and cisatracurium in 12 children (group 1) and 16 adults (group 2). All other patients of group 1 and 2 received midazolam and propofol alone; the complete procedure was performed while spontaneous breathing without intubation was maintained. In group 3 general anaesthesia and myoplegia were performed with midazolam, fentanyl, and pancuronium.

Table 1

 Characteristics of the patient groups

Sampling and assays

In groups 1–3 blood samples (0.5 ml) were taken one day before intervention or surgery (−1 day); immediately after anaesthesia onset before surgery or at the beginning of the catheterisation immediately after insertion of the sheaths, immediately after intervention with removal of the sheaths, or at the end of surgery during rewarming (+1 hour); and four hours (+4 hours), one day (+1 day, at a mean (SD) of 24.1 (3.0) hours), one to six weeks (+1 week), and two to 20 months (+2 months) after intervention or surgery. In group 4 no blood was collected at +4 hours and at +2 months. cTnI was measured by AxSYM14 microparticle enzyme immunoassay (Abbott Laboratories; cut off value 0.1 μg/l). The area under the curve (AUC), representative of the total release of cTnI in 1 ml (cTnI-AUC) was calculated.7 To take into account the differences in the total blood volume between children and adults cTnI-AUCs were weighted with the patients estimated blood volume (bodyweight × 80 ml) as a measure of the overall cTnI release for each patient.

Statistical analysis

Data were tested for normal distribution by the Kolmogorov-Smirnov test. Changes with time within a group were tested by the non-parametric Friedman test; time courses were compared between groups with analysis of variance for repeated measures. Statistical differences between groups were tested by Student’s t test, Mann-Whitney U test, or Wilcoxon test, as appropriate. Bivariate cross correlation was determined according to Pearson. Differences were regarded as significant if p < 0.05 (all statistical calculations done with SPSS version 8.0, Knowledge Dynamics, Canyon Lake, Texas, USA).

RESULTS

Among all patients of groups 1, 2, and 3 the entire procedure and course were uneventful and the ASD was closed successfully with no detectable residual shunt on colour Doppler at +1 day (groups 1 and 2) or at discharge (group 3). Diagnostic cardiac catheterisation was uneventful in all patients.

cTnI serum concentrations

cTnI concentrations were increased immediately after ASD closure until +1 day in groups 1 and 2 and until +1 week in group 3 (all p  =  0.0005, Friedman; p  =  0.005, analysis of variance groups 1, 2, and 3 versus group 4) (fig 1). The highest concentrations were reached as early as at +4 hours (group 1) or at +1 day (groups 2 and 3). The increase was more than five times higher after surgery than after Amplatzer occlusion (p  =  0.0005, analysis of variance group 3 versus group 1 or 2). At +1 week cTnI concentrations were below the cut off value in all except one patient with an Amplatzer occluder. At this time cTnI concentrations were still measurable in group 3. In group 4 cTnI concentrations remained below the cut off at all times.

Figure 1

 Time course of cardiac troponin I (cTnI) serum concentrations before, during, and after interventional (groups 1 and 2), surgical atrial septal defect (ASD) closure (group 3), or diagnostic cardiac catheterisation (group 4). Data are mean (SD). ASO, Amplatzer septal occluder. *p<0.005, group 3 v 1, 2, and 4; †p<0.040, group 1 v 4; ‡p<0.010, group 1 v 2; §p<0.005, group 2 v 4.

Total amount of released cTnI

cTnI concentration in groups 1 and 2 did not correlate with the duration of the intervention or the size of the implant device and did not differ between patients with and patients without intubation. The mean concentration of cTnI-AUC was more than four times higher in group 3 than in groups 1 and 2 (both p  =  0.0001; mean cTnI-AUC: group 1, 50.7 (55.2) ng ⋅ h/ml, group 2, 25.3 (24.0) ng ⋅ h/ml, group 3, 223.4 (193.2) ng ⋅ h/ml). In addition, the mean overall cTnI release was more than two times higher in group 3 (343 (269) μg ⋅ h) than in groups 1 and 2 (group 1, 103 (93) μg ⋅ h; group 2, 136 (114) μg ⋅ h, group 3 versus group 1 or 2, p  =  0.003). However, cTnI at +1 hour, +4 hours, and +1 day (not shown), as well as the cTnI-AUCs after occluder implantation, correlated negatively with the patient’s age (fig 2A). In contrast, overall cTnI release (representative of the total amount of released cTnI) was not age related in groups 1, 2, and 3 (fig 2B).

Figure 2

 Correlation of age with myocardial damage induced by transcatheter closure of ASD. (A) cTnI area under the curve (AUC) and (B) overall cTnI release (cTnI-AUC weighted with the estimated blood volume of individual patients) are shown versus age at intervention. Functions fitted according to Taggart et al.7 Straight line is the fitted curve; hatched lines are 5% and 95% confidence intervals of the fit. R and p values are shown for both fits. Each point represents data of an individual patient.

In groups 1 and 2 we correlated the overall cTnI release with the patient’s age, body weight, body surface area, dimensions of the device, ratio of device diameter to body surface area, and duration of the procedure. Overall cTnI release was found to correlate only with the size of the occluder in the following descending order: left atrial disc (p  =  0.0002, R  =  0.54) (fig 3), right atrial disc (p  =  0.0059, R  =  0.41), and central portion (p  =  0.0189, R  =  0.35).

Figure 3

 Correlation of myocardial damage with left atrial disc size. Overall cTnI release after myocardial damage by interventional ASD closure is shown versus size of the left atrial disc of the ASO. Linear regression: R = 0.54, p  =  0.0002. Each point represents data of an individual patient.

DISCUSSION

It is well known that cardiac surgery leads to a transient increase in cTnI serum concentration.10,11 Consistent with this, the highest cTnI concentrations in the present study were observed after surgical ASD closure. However, a mild and temporary rise of the cTnI concentration was also observed after occluder implantation, and this increase was more pronounced in children than in adults. cTnI concentrations after intervention show that this procedure leads to transient, clinically silent myocardial damage. In our opinion this is not caused by the catheterisation because, in contrast to others,13 we found that cardiac catheterisation alone did not lead to a measurable cTnI increase. Pees and colleagues5 previously reported increased cTnI concentrations over several hours after interventional closure of interatrial communication with an Amplatzer occluder. They regarded this as a result of transient, reversible myocardial membrane instability caused by the device.5 Their study focused on older patients (mean age 43.5 years) and did not examine correlations with age or device size.

Some reports suggest that the child’s myocardium is more susceptible to trauma than that of adults based on higher cTnI-AUCs after surgery at a lower age.7 However, these studies did not consider that the same amount of myocardial damage may produce a much higher cTnI concentration and cTnI-AUC in a smaller patient because of the lower blood volume. When the reduced blood volume of children is taken into account our data indicate that the overall cTnI release after occluder implantation shows similar myocardial damage irrespective of the patient’s age. Our data do not challenge the hypothesis7 that the cardiomyocytes of children are more sensitive to mechanical trauma than are those of adults, but this seems not to be relevant to interventional ASD closure.

Our results show a significant increase in myocardial injury with the size of the Amplatzer device. Its size in turn is defined by the size of the ASD but not by the size of the heart. Because the left atrial disc is the largest part of the Amplatzer device, it has the highest correlation with overall cTnI release and has the largest contact surface with the myocardium.

Coronary interventions and radiofrequency ablation in adults cause myocardial lesion associated with a rise of cTnI concentrations.12,13 Kannankeril and colleagues13 reported cTnI increase after catheter interventions such as balloon dilatation or stent implantation in the pulmonary artery. Endomyocardial biopsy and radiofrequency ablation produce myocardial lesions and, as expected, an increase in cTnI concentration. Ventricular strain and myocardial injury13 are assumed to be caused by balloon dilatation or positioning of stents into the pulmonary artery and may explain the cTnI increase. Implantation of an Amplatzer septal occluder may similarly lead to a mild myocardial lesion due to repeated balloon sizing and thus stretching of the interatrial septum. Furthermore, stenting of the defect may lead to some compression of the myocardial rim. The left and right atrial discs may produce pressure on the myocardium of the interatrial septum, contributing to a transient cTnI rise. Irritation or friction, however, does not seem to be continuous because two months after implantation no cTnI was detectable in the serum. Therefore, subsequent diagnostic troponin I measurement in suspected myocardial infarction would not be affected.

Theoretically, coronary air embolism with a somewhat more extended myocardial lesion might have been a reason for the clearly increased cTnI concentrations in two patients of the Amplatzer septal occluder group, although gross air embolism (as has been described in the literature) was not observed.15 Despite careful and apparently complete removal of air from the sheath, air bubbles can occasionally be released when the occluder is pushed forwards through the sheath that enters the left atrium and can potentially reach the coronaries.

We conclude that implantation of the Amplatzer septal occluder in ASD induces minor and transient myocardial damage, which is substantially lower than in conventional surgical closure, is age independent, and increases with the size of the occluder.

Acknowledgments

The authors thank the Saxonian States, Ministry for Science and Arts (Sächsisches Staatsministerium für Wissenschaft und Kunst, SMWK, Dresden, Germany) for their support (research grants to JB and PO) and the German Foundation for Heart Research (Deutsche Stiftung für Herzforschung, Frankfurt, Germany) for partially funding the study. The authors also thank Mrs J Richter for technical help.

REFERENCES

View Abstract

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.